Vitro Biopharma Receives Frost & Sullivan Technology Innovation Leadership Award: 2014 Best Practices for Stem Cell Tools & Technology in North America

Golden, Colo.—July 9, 2014—Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, is pleased to announce receipt of a prestigious award from Frost & Sullivan. The award is based on independent analysis of competing companies’ commitment to innovation, commercial success, application diversity and fulfillment of unmet needs. Vitro Biopharma out-ranked competing firms in all areas evaluated.

Cecilia […]

July 28th, 2014|

Vitro Biopharma Announces Advances in Stem Cell Therapy without Transplants

Golden, Colorado—June 10, 2014—Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, has been pursuing the determination of therapeutic benefits derived from activation of adult stems residing within the human body. This approach is advantageous over transplantation since many of the complications are overcome including, effects of in-vitro stem cell expansion, effects of allogeneic cells and […]

June 10th, 2014|

Stem Cell Therapy without Stem Cell Transplants Part II: New Paradigm for Treatment and Performance Enhancement

While stem cell transplants are clearly warranted for certain conditions including leukemia & lymphoma, there is growing evidence that activation of endogenous stem cells is an emerging approach to therapy. Latent stem cells require activation of specific biological signaling pathways including mobilization through chemokine signaling, proliferation/differentiation through Wnt pathway activation and epigenetic modulation of specific […]

June 6th, 2014|

Stem Cell Therapy without Stem Cell Transplants Part I: Current Status

Transplantation of hematopoietic stem cells has been widely used as an approved treatment of leukemia, lymphoma and certain autoimmune conditions for the past fifty years.  Other adult stem cells have demonstrated safety and efficacy in pre-clinical research and clinical trials.  Mesenchymal stem cell transplants have been most widely studied in animals, especially horses & dogs, […]

June 6th, 2014|

Vitro Biopharma Revenues Continue to Accelerate Towards Profitability

Golden, Colorado—May 6, 2014—Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced completion of its second fiscal quarter.  Revenues continue to show strong growth and the Company projects near-term attainment of profitable operations.  Total revenues increased three-fold (300%) in the first six months of 2014 compared to the same period in 2013 from increased product […]

May 6th, 2014|

Vitro Biopharma Products Advance Pancreatic Cancer Research

Golden, Colorado—March 11, 2013—Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced that some of its products are being utilized in advancing pancreatic cancer research including development of new diagnostic tests and new therapeutic approaches.  Pancreatic cancer remains one of the most deadly and least survivable cancers; it is asymptomatic until quite advanced and is […]

March 13th, 2014|

Vitro Biopharma Products Advance Pancreatic Cancer Research

Golden, Colorado—March 11, 2013—Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced that some of its products are being utilized in advancing pancreatic cancer research including development of new diagnostic tests and new therapeutic approaches.  Pancreatic cancer remains one of the most deadly and least survivable cancers; it is asymptomatic until quite advanced and is […]

March 11th, 2014|

Vitro Biopharma Revenues Increase in Early 2014: Plans Trials of Endogenous Stem Cell Activation for Therapeutic Benefit

Golden, Colorado—February 11, 2014—Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma,  announced that its revenues increased substantially (78%, unaudited) in its first 2014 fiscal quarter due to its growing and expanding business relationship with Neuromics, Inc.  Vitro has now commercialized bio-analytical services as the initial stage in its expansion as a Contract Research Organization (CRO).  […]

February 11th, 2014|

Vitro Biopharma’s CEO Elaborates on Merger-Driven Growth Acceleration in an Interview with the Wall Street Analyst

Golden, Colorado—November 12, 2013—Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma,  announced an interview of its CEO by Juan Costello of the Wall Street Analyst (http://thewallstreetanalyzer.com/vitro-diagnostics-otcbbvodg-ceo-interview).  In the interview, our CEO elaborated on the effect of its planned merger with Neuromics, Inc. in greater detail and provided an overview of the near-term plans to accelerate […]

November 12th, 2013|

Vitro Biopharma Announces Plans to Acquire & Merge with Neuromics, Inc.

Golden, Colorado—October 15, 2013—Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, signed a non-binding letter of intent to acquire and merge with Neuromics, Inc, a privately held life-science firm located in Minneapolis, MN.  The Merger would be structured as a reverse triangular merger, with Neuromics becoming a wholly-owned subsidiary of Vitro. Completion of the proposed […]

October 15th, 2013|